KNTE - Kinnate Biopharma  - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KNTE is currently covered by 6 analysts with an average price target of $7.11. This is a potential upside of $4.46 (168.3%) from yesterday's end of day stock price of $2.65.

Kinnate Biopharma 's activity chart (see below) currently has 16 price targets and 30 ratings on display. The stock rating distribution of KNTE is 52.94% BUY and 47.06% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 8.84% with an average time for these price targets to be met of 16.86 days.

Highest price target for KNTE is $2.59, Lowest price target is $2.59, average price target is $7.11.

Most recent stock forecast was given by BENJAMIN BURNETT from STIFEL on 26-Feb-2024.

Currently out of the existing stock ratings of KNTE, 9 are a BUY (52.94%), 8 are a HOLD (47.06%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$2.59

$5.4

11 months 18 days ago
(26-Feb-2024)

1/7 (14.29%)

$0.14 (5.71%)

4

Hold

$2

$-0.65 (-24.53%)

$2

1 years 27 days ago
(17-Jan-2024)

1/7 (14.29%)

$-0.36 (-15.25%)

57

Hold

$4

$1.35 (50.94%)

1 years 4 months 25 days ago
(19-Sep-2023)

0/5 (0%)

$2.5 (166.67%)

Buy

$2

$-0.65 (-24.53%)

1 years 4 months 25 days ago
(19-Sep-2023)

1/3 (33.33%)

$0.5 (33.33%)

57

Hold

1 years 4 months 25 days ago
(19-Sep-2023)

0/1 (0%)

$21.33 (182.78%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KNTE (Kinnate Biopharma ) average time for price targets to be met?

On average it took 16.86 days on average for the stock forecasts to be realized with a an average price target met ratio 8.84

Which analyst has the current highest performing score on KNTE (Kinnate Biopharma ) with a proven track record?

CHRISTOPHER RAYMOND

Which analyst has the current lower performing score on KNTE (Kinnate Biopharma ) with a proven track record?

TIM LUGO

Which analyst has the most public recommendations on KNTE (Kinnate Biopharma )?

Christopher Raymond works at PIPER SANDLER and has 12 price targets and 8 ratings on KNTE

Which analyst is the currently most bullish on KNTE (Kinnate Biopharma )?

Christopher Raymond with highest potential upside - $1.35

Which analyst is the currently most reserved on KNTE (Kinnate Biopharma )?

David Nierengarten with lowest potential downside - -$0.65

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?